Durvalumab After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: Inferior Outcomes and Lack of Health Equity in Hispanic Patients Treated With PACIFIC Protocol (LA1-CLICaP)

OBJECTIVES: To compare the rate disparity between outcomes (overall survival (OS), progression-free survival (PFS), and safety) of concurrent chemoradiation (cCRT) followed by durvalumab in two patient cohorts with locally advanced (LA) stage III non-small cell lung cancer (NSCLC), one non-Hispanic...

Descripción completa

Detalles Bibliográficos
Autores principales: Raez, Luis E., Arrieta, Oscar, Chamorro, Diego F., Soberanis-Piña, Pamela Denisse, Corrales, Luis, Martín, Claudio, Cuello, Mauricio, Samtani, Suraj, Recondo, Gonzalo, Mas, Luis, Zatarain-Barrón, Zyanya Lucia, Ruíz-Patiño, Alejandro, García-Robledo, Juan Esteban, Ordoñez-Reyes, Camila, Jaller, Elvira, Dickson, Franco, Rojas, Leonardo, Rolfo, Christian, Rosell, Rafael, Cardona, Andrés F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9321635/
https://www.ncbi.nlm.nih.gov/pubmed/35903685
http://dx.doi.org/10.3389/fonc.2022.904800

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9321635/
https://www.ncbi.nlm.nih.gov/pubmed/35903685
http://dx.doi.org/10.3389/fonc.2022.904800

Ejemplares similares